



Article

## LRRC15 Targeting in Soft-Tissue Sarcomas: Biological and Clinical Implications

Eytan Ben-Ami, Raul Perret, Ying Huang, Félicie Courgeon, Prafulla Gokhale, Audrey Laroche-Clary, Benjamin Eschle, Valérie Velasco, François Le Loarer, Marie-Paule Algeo, James Purcell, George Demetri and Antoine Italiano


## **Supplementary Materials**

**Supplementary Table S1.** LRRC15 expression according to grade.

Tumour characteristic		LRRC15 expression		Total
		Low *	High *	Total
Grade	1	17	1	18
	2	112	13	125
	3	221	60	281
Total		350	74	424


<sup>\*</sup> Low LRRC15 expression (H score ≤ 160); High LRRC15 expression (H score > 160).





**Supplementary Figure S1.** Preclinical activity of ABBV-085 in LRRC15-positive UPS patient derived xenograft models (**A**: JR588 and **B**: UPS7).

Cancers 2020, 12, 757 2 of 2



**Supplementary Figure S2.** Immunohistostaining of macrophages (F4/80) on PDX JR588 paraffin slices of treated mouse by (**A**) Vehicle, (**B**) Isotype ADC, (**C**) ABBV-085 antibody. (**D**) Control of F4/80 immunostaining on a Rag $\gamma$ 2C-/- spleen paraffin slice.



**Supplementary Figure S3.** LRRC15 expression on PDX JR588 paraffin slices of treated mouse by **(A)** ABBV-085, **(B)** Vehicle **(C)** Isotype.



© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).